« Return to News | Awards & Advancement

Saint Luke's Cancer Institute appoints new medical director

Friday, July 26, 2013 03:13 PM

Saint Luke's Cancer Institute (SLCI) has appointed Timothy J. Pluard, M.D., medical director. Pluard is associate professor of medicine at Washington University and clinical director, section of breast oncology at Siteman Cancer Center, a National Cancer Institute (NCI) designated Comprehensive Cancer Center, at Washington University/Barnes Jewish Hospital in Saint Louis, Mo.

Pluard was recruited by Siteman Cancer Center in 2005 as medical director of its first satellite center in St. Peters, Mo. In 2010, Pluard was appointed clinical director of breast oncology. He also was the institutional Principal Investigator for the National Surgical Adjuvant Breast and Bowel Project (NSABP) as well as all breast industry research trials. Pluard led multiple clinical trials at Siteman Cancer Center over the past eight years, and he has been recognized twice by NCI as one of the nation's top accruers in cooperative group trials.

Pluard will work to maximize growth on a regional and national level and pursue research opportunities and clinical trials.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.